U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07238712) titled 'Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor' on Nov. 16.
Brief Summary: Optimization of bendamustine-containg graft-versus-host disease (GVHD) prophylaxis to reduce the incidence of secondary haemophagocytic lymphohistiocytosis and GVHD
Study Start Date: May 10
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia
Myelodysplastic Syndromes (MDS)
Myeloprolipherative Neoplsm
Atypical Chronic Myeloid Leukemia
Intervention:
DRUG: Ruxolitinib
; Days -1 through +21: ruxolitinib 10 mg/kg/...